Title
Category
Credits
Event date
Cost
Fatty Liver Disease: The Silent Epidemic
  • Disease management
  • Transplantation
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This presentation reviews the latest evidence-based strategies for identifying, diagnosing and managing non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). The progressive form of this disease, non-alcoholic steatohepatitis (NASH), is on track to become the leading cause of liver transplantation in the United States. Learn about current guidelines, risk-stratification tools, and emerging therapies, and gain insights to improve early detection and optimize patient outcomes.

Pages